Transient elastography (FibroScan®) with controlled attenuation parameter in the assessment of liver steatosis and fibrosis in patients with nonalcoholic fatty liver disease - Where do we stand?

Table 5 Performance of controlled attenuation parameter compared with liver biopsy for the detection of various steatosis grades

Study	Etiology of CLD	Probe	Cut-off (dB/m)	AUC	Sensitivity (%)	Specificity (%)	Number of patients with liver biopsy
Steatosis grade ≥ 1
Sasso et al[98] (2010)	CLD, ALD, NAFLD	M	238	0.91	91	81	115
de Lédinghen et al[100] (2012)	NAFLD, HCV, ALD, other	M	266	0.84	69	85	112
Shen et al[102] (2014)	NAFLD, HBV	M	253	0.92	88	83	189
Kumar et al[101] (2015)	HBV, HCV, NAFLD	M	214	0.68	64	64	317
Myers et al[99] (2012)	Hepatitis, NAFLD, other	M	289	0.79	68	88	153
Chan et al[103] (2014)	NAFLD, control	M	263	0.97	91	94	101
Imajo et al[83] (2016)	NAFLD, control	M	236	0.88	82.3	91	127
Lupșor-Platon et al[105]	HCV, HBV, NAFLD, other CLD	M	260	0.81	64.8	82.3	201
Steatosis grade ≥ 2
Sasso et al[98] (2010)	CLD, ALD, NAFLD	M	259	0.95	89	86	115
de Lédinghen et al[100] (2012)	NAFLD, HCV, ALD, other	M	311	0.86	57	94	112
Shen et al[102] (2014)	NAFLD, HBV	M	285	0.92	93	83	189
Kumar et al[101] (2015)	HBV, HCV, NAFLD	M	255	0.79	77	80	317
Myers et al[99] (2012)	Hepatitis, NAFLD, other	M	288	0.76	85	62	153
Chan et al[103] (2014)	NAFLD, control	M	263	0.86	96	67	101
Imajo et al[83] (2016)	NAFLD, control	M	270	0.73	64.3	73.6	127
Lupșor-Platon et al[105]	HCV, HBV, NAFLD, other CLD	M	285	0.82	69.7	85.1	201
Steatosis grade 3
Sasso et al[98] (2010)	CLD, ALD, NAFLD	M	292	0.89	100	78	115
de Lédinghen et al[100] (2012)	NAFLD, HCV, ALD, other	M	318	0.93	87	91	112
Shen et al[102] (2014)	NAFLD, HBV	M	310	0.88	92	79	189
Kumar et al[101] (2015)	HBV, HCV, NAFLD	M	305	0.91	71	92	317
Myers et al[99] (2012)	Hepatitis, NAFLD, other	M	283	0.70	94	47	153
Chan et al[103] (2014)	NAFLD, control	M	281	0.75	100	53	101
Imajo et al[83] (2016)	NAFLD, control	M	302	0.70	64.3	73.6	127
Lupșor-Platon et al[105] (2015)	HCV, HBV, NAFLD, other CLD	M	294	0.83	83.3	82.5	201

CLD: Chronic liver disease; ALD: Alcoholic liver disease; NAFLD: Nonalcoholic fatty liver disease; HBV: Hepatitis B virus; HCV: Hepatitis C virus.